Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.

Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 306 Study Team..

Lancet Infect Dis. 2011 Dec;11(12):916-24. doi: 10.1016/S1473-3099(11)70240-7.

PMID:
21975270
2.

The future of cell culture-based influenza vaccine production.

Perdue ML, Arnold F, Li S, Donabedian A, Cioce V, Warf T, Huebner R.

Expert Rev Vaccines. 2011 Aug;10(8):1183-94. doi: 10.1586/erv.11.82. Review.

PMID:
21854311
3.

Delivery systems for intradermal vaccination.

Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR.

Curr Top Microbiol Immunol. 2012;351:77-112. doi: 10.1007/82_2011_123. Review.

4.

Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.

Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW.

Clin Vaccine Immunol. 2011 Apr;18(4):647-54. doi: 10.1128/CVI.00435-10.

5.

Bacillus Calmette-Guérin vaccination using a microneedle patch.

Hiraishi Y, Nandakumar S, Choi SO, Lee JW, Kim YC, Posey JE, Sable SB, Prausnitz MR.

Vaccine. 2011 Mar 21;29(14):2626-36. doi: 10.1016/j.vaccine.2011.01.042.

6.

The development of vaccine viruses against pandemic A(H1N1) influenza.

Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O'Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO.

Vaccine. 2011 Feb 17;29(9):1836-43. doi: 10.1016/j.vaccine.2010.12.044.

PMID:
21199698
7.

Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles.

Song JM, Kim YC, Barlow PG, Hossain MJ, Park KM, Donis RO, Prausnitz MR, Compans RW, Kang SM.

Antiviral Res. 2010 Nov;88(2):244-7. doi: 10.1016/j.antiviral.2010.09.001.

8.

Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays.

Chen X, Kask AS, Crichton ML, McNeilly C, Yukiko S, Dong L, Marshak JO, Jarrahian C, Fernando GJ, Chen D, Koelle DM, Kendall MA.

J Control Release. 2010 Dec 20;148(3):327-33. doi: 10.1016/j.jconrel.2010.09.001.

PMID:
20850487
9.

Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles.

Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM.

J Control Release. 2010 Nov 1;147(3):326-32. doi: 10.1016/j.jconrel.2010.07.125.

10.

Formulation of microneedles coated with influenza virus-like particle vaccine.

Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR.

AAPS PharmSciTech. 2010 Sep;11(3):1193-201. doi: 10.1208/s12249-010-9471-3.

11.

Dissolving polymer microneedle patches for influenza vaccination.

Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, Murthy N, Compans RW, Skountzou I, Prausnitz MR.

Nat Med. 2010 Aug;16(8):915-20. doi: 10.1038/nm.2182.

12.

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, Quan FS, Chen LM, Hogan RJ, Donis RO, Compans RW, Kang SM.

Virology. 2010 Sep 15;405(1):165-75. doi: 10.1016/j.virol.2010.05.034.

13.

Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization.

Quan FS, Kim YC, Vunnava A, Yoo DG, Song JM, Prausnitz MR, Compans RW, Kang SM.

J Virol. 2010 Aug;84(15):7760-9. doi: 10.1128/JVI.01849-09.

14.

Stability kinetics of influenza vaccine coated onto microneedles during drying and storage.

Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR.

Pharm Res. 2011 Jan;28(1):135-44. doi: 10.1007/s11095-010-0134-6.

15.

Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine.

Gill HS, Söderholm J, Prausnitz MR, Sällberg M.

Gene Ther. 2010 Jun;17(6):811-4. doi: 10.1038/gt.2010.22.

16.

Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles.

Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR.

J Infect Dis. 2010 Jan 15;201(2):190-8. doi: 10.1086/649228.

17.

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.

Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR.

J Control Release. 2010 Mar 3;142(2):187-95. doi: 10.1016/j.jconrel.2009.10.013.

18.

Prospects for developing an effective particle-mediated DNA vaccine against influenza.

Yager EJ, Dean HJ, Fuller DH.

Expert Rev Vaccines. 2009 Sep;8(9):1205-20. doi: 10.1586/erv.09.82. Review.

PMID:
19722894
19.

Transdermal immunization with low-pressure-gene-gun mediated chitosan-based DNA vaccines against Japanese encephalitis virus.

Huang HN, Li TL, Chan YL, Chen CL, Wu CJ.

Biomaterials. 2009 Oct;30(30):6017-25. doi: 10.1016/j.biomaterials.2009.07.029.

PMID:
19656560
20.

Emergence and pandemic potential of swine-origin H1N1 influenza virus.

Neumann G, Noda T, Kawaoka Y.

Nature. 2009 Jun 18;459(7249):931-9. doi: 10.1038/nature08157. Review.

Items per page

Supplemental Content

Support Center